Modified scoring system could aid biliary atresia diagnosis: Study
A modified version of the Simple Biliary Atresia Scoring System (SBASS) offers a noninvasive way for doctors to make a biliary atresia diagnosis, differentiating…
News
Telehealth program helps improve hepatitis C treatment in rural US
A peer-supported telemedicine program in the U.S. significantly increased the likelihood that hepatitis C patients in rural communities would start treatment — and ultimately…
PBC therapy Ocaliva pulled from EU market with court decision
Ocaliva (obeticholic acid) is no longer available to treat primary biliary cholangitis (PBC) across the European Union (EU), with an earlier decision…
Study: New ABCB4 mutations tied to different ages of PFIC3 onset
Two cases of progressive familial intrahepatic cholestasis type 3 (PFIC3) with markedly different ages of disease onset due to new mutations in the ABCB4…
New names given nonalcoholic fatty liver diseases fit children: Study
Almost every child and adolescent who met diagnostic criteria for forms of nonalcoholic fatty liver disease under their previous names — NAFL, NASH, or…
Vascular health checks, kidney tests urged for Alagille patients: Review
Kidney and blood vessel problems are common in people with Alagille syndrome, and while these often cause few to no symptoms, they can be…
Linerixibat eases ‘relentless’ PBC itching in Phase 3 trial, meeting goal
Treatment with linerixibat, an oral medication in development by GlaxoSmithKline (GSK), led to significant reductions in pruritus, or itching, among adults with primary…
Biomarkers of inflammation could help identify ICP, study finds
Women with intrahepatic cholestasis of pregnancy (ICP), the most common pregnancy-related liver complication, have significantly higher scores of two whole-body inflammation biomarkers than women…
Semaglutide shows liver benefits in Phase 3 MASH trial
Weekly injections of semaglutide, a medication sold in the U.S. under brand names including Ozempic and Wegovy to treat type 2 diabetes and obesity, reduced…
Maralixibat reduces itch in children with biliary atresia: Case series
Off-label treatment with Mirum Pharmaceuticals’ maralixibat led to clinically meaningful reductions in severe itching, or pruritus, in five children with biliary atresia, including…
Recent Posts
- Abnormal amino acid profile seen in biliary atresia infants after birth
- Our daughter’s PFIC diagnosis made us rethink drinking at Christmas
- Hepatitis D treatment combo granted new designations in US, EU
- Committee recommends seladelpar approval in EU for treating PBC
- Diet rich in omega-3 fatty acids may lower risk of ICP, scientists say